

STRATEC Biomedical Systems AG

Conference Call – Interim Report as of June 30, 2008

August 14, 2008

stratec[®]●●
biomedical systems



Safe Harbor Statement

Forward-looking statements involve risks. This company presentation contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we can provide no guarantee of this. This is because our assumptions involve risks and uncertainties which could result in a substantial divergence between actual results and those expected. It is not planned to update these forward-looking statements.

STRATEC's Business Objective

OEM development and manufacturing of integrated solutions for reagent and instrument partners (mainly diagnostics industry)

- Instrumentation
- Automation
- Own products
- Own technology
- Own intellectual property rights




“LIAISON®” for DiaSorin

Highlights in 2008 – YTD

- Contract signed for new development of next generation analyzer system family for Bio-Rad's blood virus division
- New development agreement with Greiner Bio-One and Maven Biotechnologies for label-free detection solution
- Share buy back program of up to 2 million Euro started in June
- Presentation of GEMINI and PURE at the AACC
- Approval of increased dividend at the Annual General Meeting
- Strong deal pipeline


Sales

6-months sales compared to annual sales



Gross Profit & Gross Profit Margin


As of June 30



- Gross profit declines by 2.0%
 - Decline in sales
 - Growth of Δ sales / overall performance


Sales Contribution by Product Group

After the first six months of 2008



EBIT & EBIT Margin


As of June 30




- EBIT margin continuously over 16%
 - Higher contribution from consumables and service materials
 - No currency-related factors
 - High margin despite increased cost related to strong development pipeline

Earnings per Share (EPS)

IFRS (Euro cent)



Cash Flow



- Cash holdings of EUR 19.7 million as of June 30, 2008 (June 30, 2007: EUR 11.0 million)
- Investment continues to involve personnel expenses in operating divisions
- Financing includes payment of record dividend of EUR 2.5 million

Consolidated Income Statement


Key Figures at a Glance

IFRS (€ 000s)	01.01. - 06.30.2008	01.01. - 06.30.2007
Sales	29,548	34,098
Overall performance	32,102	34,625
Cost of materials	15,457	17,530
[materials usage ratio] *	[~ 48.1 %]	[~ 50,6 %]
Personnel expenses	8,005	7,544
Other operating expenses	3,008	2,845
EBITDA	6,016	6,993
EBIT	4,862	5,897
EBT	5,048	5,907
Consolidated net income	3,849	4,185
EPS	0.34 €	0.37 €

* Cost of materials / overall performance

Sales

Sales compared to Overall Performance



- Consolidation of sales in 2007
 - Customer postpones launch of appliances
 - Customer postpones completion of its reagents menu

Growth Drivers

- Performance drivers of the diagnostics industry = growth drivers
- Outsourcing in the diagnostics industry – more than just a trend
- Focus on customers providing high volumes (critical mass)
- Focus on high-growth segments in the diagnostics industry
- Customer qualification process
- Post-sales processes
- Razor / razor blade concept

Future Growth Drivers


- Molecular diagnostics
- Near patient testing
- Luminescence immunoassays
- Production of systems developed by third parties (cGMP)
- Partial assumption of marketer's responsibilities

Focus in 2008

- Expansion of existing business (new releases)
- Development milestones
- Product launches
- Deal pipeline
- Maintenance / expansion of contractual structures
- External growth
- Procurement priorities
- Reduction in manufacturing costs
- Extension of value chain
- Extension of innovation leadership
- Expansion of presence in US
- Expansion of presence in China (procurement)

Forecast

Sales



CAGR 2009 onwards > 11%

EBT



CAGR 2009 onwards > 18%

Summary

- STRATEC is optimally positioned in the high-growth segments of clinical diagnostics
- Stable profitability
- 2008: great opportunities for new business
- Strategic focus: good mix of short-term and long-term components
- Consolidation in 2007 has no long-term impact
- Business model has once again proven its success

Contact

STRATEC Biomedical Systems AG

Gewerbestr. 37
75217 Birkenfeld
Germany

Tel: +49 7082 7916-0
Fax: +49 7082 7916-999
www.stratec-biomedical.de

Marcus Wolfinger
Member, Board of Management, CFO
m.wolfinger@stratec-biomedical.de

TICKER

Symbol:	SBS
Bloomberg:	SBS:GR
Reuters:	SBSG.DE
ISIN:	DE0007289001
WKN:	728900

THANK YOU!

Appendix

About STRATEC

STRATEC Biomedical Systems AG designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies.

The STRATEC Group consists of the publicly listed parent company STRATEC Biomedical Systems AG and of subsidiaries and second-tier subsidiaries in Germany, the USA, the UK, Switzerland and Romania.

Further information about STRATEC is available on the internet at <http://www.stratec-biomedical.de>.

Perspectives

- New customers for existing systems
- New agreements for existing platforms (particularly MDx)
- New agreements for new systems
- Diversification of STRATEC technology

Competitive Edges


- Technology pool
- Reputation (successful launch of 9 families of instruments by our partners in the past four years)
- Diagnostics companies increasingly focus on their core business, the development of chemical reagents (Kits). The outsourcing of instrument development presents an historic opportunity to STRATEC.

Arguments in Favor of Investment

- Solid business model based on a high level of reliability in planning resulting from long-term contracts and purchasing forecasts provided by our customers
- Sales and earnings can be reliably forecast
- We expect our company to report growth in the coming years in excess of the estimated growth of the industry

Shareholder Structure and Share

Shareholder Structure (as of: 07.31.2008)



■ Fixed shareholdings
(pre-IPO shareholders)

■ Free float *

* pursuant to Deutsche Börse AG

Share

IPO	Aug. 1998
Capital increase	< 10%, Mar. 2002
	< 10%, Sep. 2005
Number of shares	11,421,663
Share price (08.14.2008)	Euro 17.20
Market capitalization	Euro 196 million

STRATEC-Partners



DADE BEHRING



Financial Calendar

- 08.14.2008** Publication of 6 month report
- 10.02.2008** German Pharma & Healthcare Conference, Zürich, Switzerland / Organized by: Deutsche Börse Group
- 10.16.2008** Life Sciences Forum, Frankfurt am Main, Germany
Organized by: Commerzbank
- 11.11.2008** Deutsches Eigenkapitalforum, Frankfurt am Main, Germany / Organized by: Deutsche Börse Group
- 11.12.2008** WestLB Deutschland Conference, Frankfurt am Main, Germany / Organized by: WestLB
- 11.18.2008** Publication of 9 month report
- 11.26.2008** HSBC European Healthcare Conference, London, UK
Organized by: HSBC

Partially incomplete / Subject to amendment